|Bid||2.7000 x 1400|
|Ask||2.7200 x 1200|
|Day's Range||2.6106 - 2.7300|
|52 Week Range||2.6106 - 15.9300|
|Beta (3Y Monthly)||1.34|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In this article we are going to estimate the intrinsic value of Mersana Therapeutics, Inc. (NASDAQ:MRSN) by taking the...
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is not uncommon among falling knives. Warning! GuruFocus has detected 2 Warning Signs with NCSM. The closing price on Friday was 4.1% off the 52-week low of $3.93 and 355% from the 52-week high of $18.6.
The latest earnings update Mersana Therapeutics, Inc. (NASDAQ:MRSN) released in December 2018 indicated company earnings became less negative compared to the previous year's level - great news for investors Below,Read More...
Mersana Therapeutics Inc (NASDAQ: MRSN ) shares, which went public in March 2018, was hit with its first bearish rating Monday in the absence of any stock-impacting data readouts over the next 12 months. ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 28) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Abbott ...
Mersana executives discussed data from its ovarian and lung cancer drug trial Wednesday. The biotech also plans to disclose its next clinical candidate in the second half of 2019.
Mersana Therapeutics, Inc. (NASDAQ:MRSN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is MRSN Read More...